Assessing nerve damage biomarkers in organophosphate exposure
Assessment of the Prognostic Value of Nerve Damage Biomarkers in Acute and Chronic Organophosphate Toxicity
This study is trying to see how exposure to certain pesticides affects nerve health by looking at specific markers in people who have been exposed, both recently and over a long time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 90 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Alexandria University Academic / other |
| Locations | 1 site (Alexandria) |
| Trial ID | NCT06021262 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the prognostic value of neuroinflammatory markers and the genotoxic effects of organophosphate pesticides in individuals with acute and chronic exposure. It will conduct a comprehensive proteomic and metabolomic analysis alongside traditional markers of inflammation and oxidative stress. The study will include a total of 90 participants, including a control group matched for age and gender, to better understand the impact of organophosphate exposure on nerve health.
Who should consider this trial
Good fit: Ideal candidates include individuals with acute or chronic exposure to organophosphates, as well as healthy individuals for the control group.
Not a fit: Patients with neurological diseases or those who do not meet the inclusion criteria will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and therapeutic strategies for patients affected by organophosphate toxicity.
How similar studies have performed: While there is ongoing research into neuroinflammatory markers and organophosphate toxicity, this specific approach combining proteomic and metabolomic profiling is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * For the control group: healthy individuals without previous exposure to organophosphates, with the specified age limits. * For the acute exposure group: patients with acute exposure to organophosphates, with the specified age limits * For the chronic exposure group: patients with chronic exposure to organophosphates, with the specified age limits No restrictions on comorbidities in the three groups except those mentioned under Exclusion Criteria Exclusion Criteria: * Pediatric patients. * Patients with neurological diseases (Parkinsonism, epilepsy, Alzheimer's disease, etc.) * Patients who does not meet the inclusion criteria.
Where this trial is running
Alexandria
- Alexandria Main University Hospital — Alexandria, Egypt (Recruiting)
Study contacts
- Study coordinator: Ahmed F. El Yazbi, professor
- Email: Ayazbi@aiu.edu.eg
- Phone: 01155881772
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.